# Case Report: A case of pediatric persistent refractory ITP responsive to avatrombopag

## TL;DR

A 6-year-old girl with persistent ITP showed improvement after treatment with avatrombopag when standard therapies failed.

## Contribution

Demonstrates avatrombopag's effectiveness in treating refractory pediatric ITP.

## Key findings

- Standard therapies failed to improve the patient's ITP.
- Avatrombopag led to significant clinical improvement in the patient.

## Abstract

Immune thrombocytopenia (ITP) is a rare hematologic disorder characterized by low platelet counts due to an immune-mediated destruction of platelets. While corticosteroids, intravenous immunoglobulin (IVIG) are the mainstays of treatment, a subset of patients may remain refractory to these therapies. Here, we present a case of a 6-year-old girl diagnosed with refractory ITP, who failed to respond to standard therapies but showed a remarkable clinical improvement with avatrombopag, a thrombopoietin receptor agonist.